RELMADA THERAPEUTICS, INC. — Director's Dealing 2019

Dec 23, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2019-12-19

Reporting Person: Kelly Paul Edward (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-19	Options to purchase common stock	$43.47	A	150000	Acquired	2029-12-19	Common Stock (150000)	Direct

Footnotes

F1: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.